Inflammatory Markers and Aortic Aneurysms: Exploring the Role of Hs-CRP and MHR in Ascending Aortic Aneurysm Development

Abstract

Background

Aortic aneurysms, particularly those affecting the ascending aorta, pose significant health risks due to their potential to cause life-threatening complications such as rupture and dissection. While the etiology of ascending aortic aneurysms has traditionally been associated with non-inflammatory processes, emerging evidence suggests a potential role of inflammation in their development.

Methods

This study investigates the relationship between inflammatory markers and ascending aortic aneurysms, focusing on high-sensitivity C-reactive protein (hs-CRP) and the monocyte-to-HDL ratio (MHR). A total of 135 patients with ascending aortic aneurysms and 40 control subjects underwent comprehensive evaluations, including echocardiography, computed tomography imaging, and serum biomarker measurements.

Results

The results indicate significantly elevated levels of hs-CRP and MHR in patients with ascending aortic aneurysms compared to the control group, suggesting a potential inflammatory component in the pathogenesis of these aneurysms. However, the precise mechanisms underlying this association remain to be elucidated.

Conclusion

Despite limitations such as the cross-sectional study design and relatively small sample size, this study provides valuable insights into the potential involvement of inflammation in ascending aortic aneurysms. Further research, including longitudinal studies and histopathological analysis of aortic tissue, is warranted to confirm these findings and explore the utility of inflammatory markers as diagnostic and prognostic indicators in this patient population.

Introduction

Thoracic aortic aneurysms (TAA) have an estimated incidence of at least 5–10 per 100,000 person-years.¹ The cause, natural history, and treatment vary depending on the location of the TAA. Aortic root or ascending aortic aneurysms are most common types (approximately 60%), followed by aneurysms of the descending aorta (approximately 35%) and aortic arch (<10).² There are many causes of aneurysm, like heritable disorders, genetic disorders, and degenerative, mechanical, and infectious diseases. Both Abdominal and ascending aortic aneurysms share the same risk factors, including male gender, smoking, age, history of myocardial infarction, hypertension, low high-density lipoprotein (HDL) cholesterol concentration, and a high concentration of total serum cholesterol.^3,4 Besides these well-known risk factors, primary hyperaldosteronism is an uncommon risk factor for acute aortic dissection.⁵ The importance of ascending aortic aneurysms resides in their capacity to induce life-threatening complications and the requirement for efficient management strategies. Ascending aortic aneurysms have a high likelihood of causing serious health problems and death. If not properly treated, there is a risk of life-threatening complications such as rupture and dissection.⁶ In a recent study, 27% of patients with AAA also presented with an ascending AA, most of whom were women, and the elderly.⁷ These coexistences of abdominal aneurysm and ascending aneurysm bring to our mind the possibility of sharing the same etymology. The inflammation in the etymology of AAA has been demonstrated in many studies, but it is still not well known if the inflammation has a role in the development of aneurysms in the ascending aorta. The coexistence of inflammatory cells with markers of apoptotic vascular cell death in the media of ascending aortas with aneurysms and type A dissection raises the possibility that activated T cells and Macrophages may contribute to the elimination of smooth muscle cells and the degradation of the matrix associated with thoracic aortic aneurysms and dissections.⁸ Several studies showed the role of inflammation and the relationship between CRP and AAA.^9,10 Also, it has been shown that CRP is specifically deposited on the interface between the atheroma and the damaged aortic wall in AAA, and in the same study, there was a high level of CRP in patients with ascending Aortic aneurysm.¹¹ Since aortic aneurysms are mainly asymptomatic during their clinical course until their complications—which may be lethal—serum biomarkers for their early diagnosis are a necessity.

C-reactive protein (CRP) and high-sensitivity CRP C-reactive protein (hs-CRP) serves as indicators of widespread inflammation and have been linked to a range of health conditions, such as cardiovascular diseases. Research has demonstrated a correlation between increased levels of hs-CRP and vascular remodeling as well as the rupture of coronary atherosclerotic plaques.¹² This suggests that hs-CRP plays a role in the advancement of atherosclerotic disease. Studies have shown that elevated levels of plasma D-dimer and hypersensitive C-reactive protein (hs-CRP) are indicative of aortic dissection and aneurysm.¹³ The aim of this study was to measure hs-CRP levels in people with isolated ascending aortic aneurysm and compare them with control subjects to assess whether this marker can be of value in this group of patients.

Methods

Study Population

We enrolled a total of 135 consecutive patients diagnosed with ascending aortic aneurysm (Asc AA) with a mean age of 57.1 ± 7.3 years, of which 76 (80%) were men. Additionally, 40 control subjects with a mean age of 54.2 ± 6.8 years, including 8 (20%) men, were recruited from the outpatient cardiology department at Ordu State Hospital. All patients underwent an echocardiography examination conducted by two independent cardiologists. The ascending aorta was assessed in transthoracic parasternal long-axis view. Patients with a diameter above 40 mm were included in the patient group (95 patients), while those with a diameter below this threshold were included in the control group (40 patients). Full blood count and biochemical tests were performed on the day of the outpatient visit, and demographic patient characteristics were obtained through interviews, including gender, age, smoking history, hypertension, cardiovascular medication (including statins), family history, presence of diabetes mellitus (use of insulin or oral antidiabetic drugs), and coronary artery disease status.

CT Imaging Techniques

All patients underwent computed tomography (CT) imaging. The diameter of the ascending aorta was independently determined from the echocardiography results by a radiologist. For each examination, the radiologist generated double-oblique short-axis views through the proximal aorta using an independent imaging workstation (Vital Images workstations, Vitrea 6.0.1 3D analysis software, Minnetonka, MN). Measurements were manually obtained from these images to determine the largest diameter at the annulus, sinuses (cusp to cusp), Sino tubular junction, and mid-ascending aorta.

Determination of Serum CRP

Venous blood samples were drawn on the day of the echocardiography examination and immediately centrifuged for 10 minutes at 1200 rpm and at 4°C. Serum samples were stored at −20°C until analysis. The highly sensitive (hs-CRP) IMMULITE CRP method (Diagnostic Product Corporation) with a detection limit of 0.10 mg/L was used to measure the levels of C-reactive protein (CRP). Patients were excluded if there was evidence of acute illness or infection, active inflammatory conditions, malignancy, or corticosteroid use.

Exclusion Criteria

Patients with any valve diseases, such as bicuspid valve, aortic valve regurgitation, and aortic valve stenosis, were excluded from the study. Only patients with isolated ascending aorta aneurysms were included.

Results

The baseline characteristics of the AA+ and AA- patient groups were summarized in Table 1. A total of 135 patients were included in the analysis, comprising 95 (70.3%) AA+ patients with a mean age of 57.0±7.3 years, of whom 76 (80%) were men, and 40 (29.7%) control subjects with a mean age of 54.2±6.8 years, of whom 8 (20%) were men. No statistically significant differences were observed between the groups in terms of antihypertensive drug usage, β-blocker usage, hyperlipidemia, coronary artery disease, hypertension, or diabetes mellitus. However, several parameters differed significantly between the AA+ and control groups. Some of the things that were more common in AA+ patients than in the control group were gender (p=0.006), age (p=0.04), creatinine levels (0.86±0.13 vs 0.81±0.12; p=0.043), hs-CRP levels (4.0±2.4 vs 2.2±1.8; p<0.001), WBC count (7.0±1.6 vs 6.3±1.2; p=0.014), and MHR (13.1±3.96 vs 9.69±3.88; p<0.001). AA+ patients had lower HDL levels (42.2±7.2 vs 50.4±11.9; p<0.001), RDW (12.22±1.68 vs 12.74±0.94; p=0.012), MPV (7.89±1.55 vs 9.99±1.54; p<0.001), and platelet count (246±62 vs 274±66; p=0.019) than controls. Age, gender, creatinine, hs-CRP, LDL, HDL, WBC count, RDW, MPV, and MHR were some of the variables that were significantly linked to AA in a univariate analysis (Table 2). Hs-CRP (OR 1.527, 95% CI 1.117 to 2.086, p=0.008), MPV (OR 0.381, 95% CI 0.250 to 0.582, p<0.001), and platelet count (OR 0.980, 95% CI 0.968 to 0.993, p=0.002) were still able to predict AA on their own (Table 3). Furthermore, in ROC analysis, a cutoff value of 2.15 for hs-CRP demonstrated a sensitivity of 68% and a specificity of 60% for predicting AA patients (AUC: 0.723, p<0.001) (Figure 1). These findings underscore the importance of hs-CRP, MPV, and platelet count as potential biomarkers for identifying AA patients. Correlation analyses were performed. The findings showed that hs-CRP levels were significantly positively related to the presence of AA (r = 0.45, p < 0.001). This means that higher hs-CRP levels are linked to a higher chance of having AA. Similarly, MHR was also positively correlated with AA (r = 0.39, p < 0.001), suggesting that elevated MHR is associated with AA. These correlations suggest a potential causal relationship in which inflammatory processes, as indicated by elevated hs-CRP, may contribute to the development or progression of AA. The association of MHR with AA could reflect the interplay between inflammation and metabolic health, indicating a more complex underlying pathophysiology. However, more research is required to definitively establish causation.

Table 1.

Baseline Characteristics and Laboratory Findings

	Aa(+)	Aa(-)	P
Age	57.0±7.3	54.2±6.8	0.04
Creatinine	0.86±0.13	0.81±0.12	0.043
Gender(male)	%80	%20	0.006
Antihypertensive drug usage	%71.6	%28.4	0.549
B-blocker usage	%73.6	%26.4	0.511
Hyperlipidemia	%71.2	%28.8	0.812
Coronary artery disease	%63.2	%36.8	0.458
Hypertension	%71.4	%28.6	0.699
Diabetes mellitus	%70.4	%29.6	1.000
hs-CRP(mg/l)	4.0±2.4	2.2±1.8	<0.001
Fasting glucose (mg/dl)	101.9±18.4	99.1±13.7	0.518
Hba1c(%)	5.7±0.4	5.7±0.3	0.754
Total cholesterol(mg/dl)	205.99±±39.11	205.78±43.95	0.978
LDL (MG/DL)	132.15±34.08	128.55±34.98	0.579
HDL(MG/DL)	42.2±7.2	50.4±11.9	<0.001
Triglycerides	169±86	147±70	0.112
ALT(U/L)	27.43±20.3	25.0±11.6	0.687
AST(U/L)	24.27±9.63	25.38±11.22	0.979
GGT(U/L)	25.89±9.82	25.35±9.48	0.767
Uric acid(mg/dl)	5.51±1.25	5.17±1.17	0.148
WBC(103/µL)	7.0±1.6	6.3±1.2	0.014
Hemoglobin(g/dl)	14.21±1.43	13.95±1.63	0.361
RDW(%)	12.22±1.68	12.74±0.94	0.012
MCV(FL)	86.49±3.98	86.47±4.13	0.972
Neutrophil(103/µL)	3.9±1.2	3.5±0.9	0.09
Lymphocyte(103/µL)	2.3±0.6	2.1±0.5	0.374
Neutrophil/ lymphocyte ratio	1.8±0.6	1.7±0.5	0.591
MPV(FL)	7.89±1.55	9.99±1.54	<0.001
Platelet(103/µL)	246±62	274±66	0.019
MHR	13.1±3.96	9.69±3.88	<0.001

Notes: Bold P-values indicate statistical significance. Data are given as mean ±SD, median (interquartile range) or n (%).

Abbreviations: Aa, aortic aneurysm; ALT, alanin aminotransferaz; AST, aspartat aminotransferaz; Hba1c, hemoglobin a1c; HDL, high density lipoprotein cholesterol; hs-CRP, high sensitive c reactive protein; LDL, low density lipoprotein cholesterol; MCV, mean corpuscular volume; MHR, monocyte/hdl; MPV, mean platelet volume; RDW, red cell distribution width; WBC, white blood cell.

Table 2.

Univariate Logistic Regression Analysis

	OR	95% CI	p-value
Age	1.053	1.001–1.107	0.047
Creatinine	1.202	1.05–1.606	0.046
Gender	0.35	0.163–0.751	0.007
HDL (mg/dL)	0.905	0.862–0.951	<0.001
Hs-CRP(mg/L)	1.467	1.202–1.790	<0.001
MHR	1.276	1.132–1.438	<0.001
MPV(fL)	0.458	0.344–0.610	<0.001
RDW(%)	0.746	0.547–1017	0.063
Platelet(103/µL)	0.993	0.988–0.999	0.025
WBC(103/µL)	1.397	1.069–1.826	0.014

Note: Bold P-values indicate statistical significance.

Abbreviations: hs-CRP, High Sensitive C Reactive Protein; HDL, High Density Lipoprotein Cholesterol; RDW, Red Cell Distribution Width; MPV, Mean Platelet Volume; WBC, White Blood Cell.

Table 3.

Predictors of Aortic Aneurysm in Multivariate Logistic Regression Analyses

	OR	95% CI	p-value
Hs-CRP(mg/L)	1.527	1.117–2.086	0.008
MPV(fL)	0.381	0.250–0.582	<0.001
Platelet(103/µL)	0.980	0.968–0.993	0.002

Note: Bold P-values indicate statistical significance.

Abbreviations: OR, odds ratio; CI, confidence interval; MPV, Mean Platelet Volume.

Figure 1.

The ROC curve analysis of hs-CRP in predicting ascending aortic aneurysms.

Discussion

This study demonstrated that hs-CRP and the monocyte/HDL ratio are elevated in patients with ascending AA compared to the control group, suggesting a potential role for inflammation in the development of ascending AA. The etiology of ascending AA differs from that of AAA, where inflammation plays a significant role. Early 1930s researchers Erdheim et al described the etiology of ascending aortic aneurysms as medial degeneration, which is characterized by non-inflammatory lesions and a noticeable loss of smooth muscle cells and elastic fibers within the arterial media layer.¹⁴ The inflammatory process in the arterial wall encompasses multiple mechanisms, such as destructive remodeling, inflammation, angiogenesis, biomechanical wall stress, and molecular genetics.¹⁵ Observations have shown that inflammatory changes occur within the tissue of an aneurysm, including an increase in local AngII signaling and a change in the phenotype of smooth muscle cells. These changes contribute to the development of ascending aortic aneurysms.¹⁶ Recent evidence suggests a convergence in risk factors between ascending AA and AAA, indicating a potential inflammatory component in ascending aortic aneurysm development. Several studies have reported elevated inflammatory biomarkers in patients with ascending AA. For instance, Dolapoglu et al found increased CRP levels in patients with ascending AA and proposed the CRP/albumin ratio as a potential marker for rapid growth in ascending aortic aneurysms.¹⁷ Similarly, Jiyoung Yu et al reported high CRP levels in patients with ascending AA.¹¹ Rumin HE et al found evidence that inflammatory infiltrates, especially T cells that express Fas, may play a role in TAAs, which are similar to AAAs.⁸ In our study, people with ascending AA had higher levels of hs-CRP and a high ratio of monocytes to HDL compared to the control group. This finding aligns with previous research showing a decrease in HDL levels in AAA patients.¹⁸ It is known that HDL can help prevent the growth of aortic aneurysms.¹⁹ The lower HDL levels in our study’s ascending AA patient group may be what caused the rise in the monocyte/HDL ratio. However, whether this finding reflects the anti-inflammatory and antioxidant effects of HDL or merely serves as a surrogate marker of cardiovascular health remains uncertain. New research suggests that HDL molecules not only take cholesterol off of macrophages, but they also stop macrophages from moving and control how activated and stuck together monocytes are, which could affect the development of ascending AA.²⁰ The elevation of hs-CRP and MHR in ascending AA patients indicates the presence of inflammation, but whether it is a cause or a consequence remains unclear, especially considering that 63% of our patients had coronary artery disease. However, Increased concentrations of hs-CRP and MHR have been associated with the existence and advancement of aortic aneurysms, indicating its potential usefulness as a diagnostic biomarker for identifying individuals who are at risk of developing ascending aortic aneurysms.²¹ Further clarification would require histopathological analysis of aortic tissue, which was not feasible in our study.

Study Limitations

Despite its contributions, this study has several limitations that should be acknowledged. Firstly, its cross-sectional design limits the ability to establish causality between inflammatory markers and AA development. Longitudinal studies are needed to elucidate the temporal relationship between inflammation and AA progression. Additionally, the relatively small sample size and single-center nature of the study may limit the generalizability of the findings. Future research with larger, more diverse cohorts is warranted to validate these Results and enhance their clinical relevance. Furthermore, the lack of histopathological analysis of aortic tissue precludes a detailed understanding of the underlying inflammatory processes in AA. Incorporating histological data in future studies could provide valuable insights into the mechanisms driving AA pathogenesis. Finally, the fact that a lot of patients have other health problems at the same time, like coronary artery disease, can make it hard to figure out what the levels of inflammatory biomarkers mean. Accounting for these confounders in future analyses would help clarify the specific role of inflammation in AA development.

Conclusion

This study provides valuable insights into the potential involvement of inflammation in the development of ascending aortic aneurysms (AA). Higher amounts of hs-CRP and the monocyte-to-HDL ratio (MHR) were found in people with AA compared to the control group. This suggests that inflammation may play a part in the development of AA. The increased levels of hs-CRP and MHR indicate a substantial inflammatory contribution to the development of ascending aortic aneurysms. This suggests that chronic inflammation plays a role in the degradation of the extracellular matrix, loss of smooth muscle cells, and upregulation of proteolytic enzymes, all of which contribute to the progression of the aneurysm. These results show that more research needs to be done on the inflammatory processes that lead to AA and on how inflammatory markers might be useful as diagnostic and prognostic tools in this group of patients.

Ethical Consideration

The study adhered to the principles of the Declaration of Helsinki and was approved by the Ordu state hospital ethics committee. Participants provided informed consent, and measures were taken to ensure patient confidentiality and data protection. The protocol minimized potential biases and conflicts of interest were disclosed. The research aimed to provide valuable insights into inflammatory markers and ascending aortic aneurysms.

Disclosure

The authors report no conflicts of interest in this work.